3600 (3600) Fair Value & Analysis

Healthcare · Market cap HK$5.8B

3 3600 3600 · HK

PriceHK$6.14

Fair ValueHK$13.21

Upside+115.1%

Quality76/100

Watch 3600 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$9.44 – HK$16.48

Fair value as of: Jul 2, 2026

From 26 valuation models · updated today

Share price +6.8% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$3.92 – HK$6.50 · fair‑value band HK$9.44 – HK$16.48 · the HK$6.14 price screens below the HK$13.21 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

3600 (3600) currently trades at HK$6.14, while our model-based Fair Value estimate is HK$13.21 — implying the stock looks roughly 115.1% undervalued today. We read business quality at 76/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

Over the trailing twelve months, 3600 generated revenue of HK$3.7B at a net margin of 16.0%. Revenue grew 14.4% year over year. It earns a return on equity of 20.0%. The balance sheet holds a net cash position of HK$113M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$3.7B

Revenue growth (YoY) +14.4%

Net margin 16.0%

Return on equity 20.0%

Free cash flow HK$691M FY2025

P/E ratio 9.6

More key figures

Operating margin 20.6%

EPS (TTM) HK$0.3000

Dividend yield 4.3%

EPS growth (YoY) +62.1%

Net cash HK$113M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

3600 reported revenue of HK$3.7B in FY2025 versus HK$3.0B in FY2021, a compound +6.0%/yr. Reported net income was HK$597M in FY2025, compounding +13.4%/yr from FY2021.

Revenue +6.0%/yr

FY21 HK$3.0B

FY22 HK$2.8B

FY23 HK$3.2B

FY24 HK$3.4B

FY25 HK$3.7B

Net income +13.4%/yr

FY21 HK$361M

FY22 HK$220M

FY23 HK$404M

FY24 HK$408M

FY25 HK$597M

Is 3600 fairly valued? → Check now

Similar stocks

6 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
Intuitive Surgical, Inc ISRG	$422.06	$165.35	-61%
EssilorLuxottica Société anonyme ESLOF	$205.86	$114.90	-44%
HOYA Corporation HOCPY	$178.46	$103.27	-42%
Medline Inc MDLN	$36.54	$30.66	-16%
Becton, Dickinson and Company BDX	$147.79	$124.26	-16%
Alcon Inc ALC	$65.18	$44.21	-32%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 3600 (3600) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$13.21 versus a price of HK$6.14 — about +115% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 3600?

Our model-based fair value for 3600 is HK$13.21 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$6.14.

What is the quality score of 3600?

3600 has a Quality Score of 76/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 3600 (3600)?

3600 reported trailing-twelve-month revenue of about HK$3.7B (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 3600?

The net profit margin of 3600 is about 16.0%, meaning it keeps roughly 16.0% of revenue as net income. Based on the latest reported figures.

Does 3600 pay a dividend?

3600 currently shows a dividend yield of about 4.31% relative to its recent price (as of Jul 2, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.